Last reviewed · How we verify
Ortho-McNeil Janssen Scientific Affairs, LLC — Portfolio Competitive Intelligence Brief
2 marketed
0 filed
1 Phase 3
0 Phase 2
1 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| OROS MPH Tablets | OROS MPH Tablets | marketed | Central nervous system stimulant; dopamine-norepinephrine reuptake inhibitor | Dopamine transporter (DAT); norepinephrine transporter (NET) | Psychiatry / Neurology | |
| OROS MPH | OROS MPH | marketed | Central nervous system stimulant; dopamine-norepinephrine reuptake inhibitor | Dopamine transporter (DAT); norepinephrine transporter (NET) | Psychiatry / Neurology | |
| tapentadol IR | tapentadol IR | phase 3 |
Therapeutic area mix
- Psychiatry / Neurology · 2
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
Subscribe to ongoing alerts
Every new pipeline event for Ortho-McNeil Janssen Scientific Affairs, LLC:
- Ortho-McNeil Janssen Scientific Affairs, LLC pipeline updates — RSS
- Ortho-McNeil Janssen Scientific Affairs, LLC pipeline updates — Atom
- Ortho-McNeil Janssen Scientific Affairs, LLC pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Ortho-McNeil Janssen Scientific Affairs, LLC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ortho-mcneil-janssen-scientific-affairs-llc. Accessed 2026-05-17.